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Return-to-health effect of modern combined
antiretroviral therapy potentially predisposes HIV
patients to hepatic steatosis
Raphael Mohr, MDa,b, Christoph Boesecke, MDa,b, Leona Dold, MDa,b, Robert Schierwagen, PhDa,
Carolynne Schwarze-Zander, MDa,b, Jan-Christian Wasmuth, MDa,b, Insa Weisensee, MDa,
Jürgen Kurt Rockstroh, MDa,b, Jonel Trebicka, MD, PhDa,c,d,e,
∗
Abstract
Prevalence and risk factors for hepatic steatosis (HS) in the human immunodeﬁciency virus (HIV)-positive population of western
countries are controversially discussed and potentially confounded by coinfection with viral hepatitis. Signiﬁcant HS (more than 10%
of hepatocytes) can be accurately assessed using controlled attenuation parameter (CAP) determination. Aim of this study was to
assess prevalence and factors associated with signiﬁcant HS in HIV monoinfected patients.
A total of 364 HIV-infected patients (289 monoinfected) were included in this prospective, cross-sectional study. All patients
underwent CAP determination. Steatosis was classiﬁed as S1 (signiﬁcant steatosis) with CAP>238dB/m, S2 with CAP>260dB/m,
and S3 with CAP>292dB/m. Multivariable logistic regression analyses were performed to assess the factors associated with HS in
this cohort.
Signiﬁcant HSwas detected in 118monoinfected patients (149 in the total cohort). In the total cohort as well as in themonoinfected
patients alone, HS grade distribution showed a similar pattern (S1:29%, S2:34%, and S3:37%). Interestingly, patients with HS had a
longer history of HIV infection and combined antiretroviral therapy (cART). Interalia, age, gender, ethnicity, andmetabolic factors were
strongly associated with HS, while body mass index (BMI), triglyceride, and glycated hemoglobin (HbA1c) levels were independently
associated with signiﬁcant HS.
HS is highly prevalent among HIV monoinfected patients. Although metabolic risk factors, such as obesity and poorly controlled
diabetes, are independently associated with HS in HIVmonoinfected patients, cART and control of HIV seem to play an indirect role in
the development of HS, probably through the return-to-health effect.
Abbreviations: CAP = controlled attenuation parameter, cART = combined antiretroviral therapy, CD4 = cluster of differentiation
4, DM = diabetes mellitus, HbA1c = glycated hemoglobin, HCV = hepatitis C virus, HDL = high-density lipoprotein, HIV = human
immunodeﬁciency virus, HS = hepatic steatosis, NAFLD = nonalcoholic fatty liver disease, NASH = nonalcoholic steatohepatitis.
Keywords: CAP, cART, HIV monoinfection, liver injury, NAFLD
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1. Introduction
Present day combined antiretroviral therapy (cART), leading to
permanent suppression of human immunodeﬁciency virus (HIV)
replication, has dramatically improved survival of HIV-infected
patients. Chronic liver disease has emerged as an increasingly
signiﬁcant contributor to nonacquired immune deﬁciency
syndrome related morbidity and mortality in the HIV-infected
population.[1] Independent of coinfection with hepatotropic
viruses, increased rates of liver ﬁbrosis and steatosis have been
observed.[5–7] On the one hand, HIV induces metabolic changes;
on the other hand, long-term exposure to antiretroviral drugs
may exert toxicities (in particular mitochondrial toxicity,
dyslipidemia, and insulin resistance)[2–4,33], which may further
contribute to the development of clinically relevant liver
disease.[8–10] Hepatic steatosis (HS) may then progress to
nonalcoholic steatohepatitis (NASH), an emerging cause of
hepatocellular carcinoma.[11] Furthermore, liver steatosis may
predispose to acute liver failure, especially when those patients
are exposed to additional hepatic risk factors.[12]
Little information is available on the prevalence and potential
risk factors for liver steatosis among HIV monoinfected patients.
Indeed, most of the currently existing data on HS solely derives
from HIV/hepatitis C virus (HCV) coinfected patients. In these
coinfected patients, the prevalence rate for HS ranges between
20% and 80%.[6,11,13,14] In a recently published, large Canadian
study with more than 22% coinfected patients, no difference in
the grade of steatosis was observed between co- and mono-
infected patients.[15] Importantly, coinfection with HCV is a
strong confounder for HS, not only due to changes in the
measurement as a result of inﬂammation and ﬁbrosis, but also
because it is dependent on the HCV genotype.
With regard to risk factors promoting steatosis in HIV
infection, little is known and this issue is controversially
discussed.[16–22] Steatosis is mostly associated with metabolic
risk factors (obesity, diabetes, and dyslipidemia) in the general
population and might lead to severe liver disease. In HIV-positive
population, the metabolic risk factors still play a role for the
development of steatosis, the impact of long-term exposure to
antiretroviral regimes for liver injury and speciﬁcally for steatosis
has also been discussed. A recently published meta-analysis
demonstrated that body mass index (BMI), waist circumference,
diabetes mellitus (DM), hypertension, triglycerides, and cluster of
differentiation 4 (CD4) cell count were associated with
nonalcoholic fatty liver disease (NAFLD), whereas HIV speciﬁc
parameters like HIV viral load, duration of HIV, duration of
cART, and nadir CD4 count were not.[23]
This study aimed to examine in more detail the prevalence and
risk factors for severe HS in a large cohort of HIV monoinfected
patients from the Infectious Diseases outpatient clinic at Bonn
University.
2. Methods
2.1. Patients
This cross-sectional prospective study included 364 HIV-infected
patients followed at the Infectious Diseases outpatient clinic at
Bonn University. Patients with conﬁrmed HIV infection and self-
reported alcohol intake of no more than 30g/day (male
participants) or 20g/day (female participants) were eligible for
inclusion. The use of anabolics or hormons was not reported by
patients but would have exclusion criteria. To assess the potential
effect of concomitant HCV or hepatitis B virus coinfection, as well
as to minimize the potential effect of confounders, analyses were
performed on the total study population and the group of 289HIV
monoinfected patients (Fig. 1A). Blood collection and controlled
attenuation parameter (CAP) measurement were performed
during a regular scheduled visit at our outpatient clinic. Informed
consent was obtained from each patient included in the study and
the study protocol conforms to the ethical guidelines of the 1975
Declaration of Helsinki as reﬂected in the approval by the
institution’s human research committee (279/14).
2.2. Data acquisition and follow-up
Laboratory work-up of metabolic (glycated hemoglobin
[HbA1c], cholesterol, low-density lipoprotein, high-density
lipoprotein [HDL], triglycerides, transaminases, bilirubin, creat-
inine, platelets, albumin, and thyroid-stimulating hormone),
inﬂammatory/immunologic (c-reactive protein, CD4, and CD8),
and HIV-relevant disease markers (viral load) was performed at
the same time as transient elastography. Demographic and
clinical characteristics as well as data on health trajectory of HIV
infection and antiretroviral treatments were collected from the
patient’s health record and our department’s database. Current
comedication, alcohol consumption, and smoking status were
recorded and the actual BMI was assessed.
2.3. Hepatic steatosis measurement
CAPmeasures the degree of ultrasound attenuation by hepatic fat at
the central frequencyof theFibroScanMprobe, simultaneouslywith
liver stiffness measurement. The technique can establish presence of
HSaffectingmore than10%of thehepatocytes in the liver biopsy[24]
and has been validated in different groups of patients.[25–27]
CAP measurement was assessed using FibroScan 502 touch
(ECHOSENS, France) performed by experienced and trained
operators. According to standards, examinations with at least 10
valid measurements, a low variability deﬁned as an interquartile
range (IQR/M) smaller than 30% of the median value, and a
successful acquisition rate of at least 60% were considered
reliable and were approved for analysis.[28]
The optimal threshold of CAP for the detection of HS is
unknown in NAFLD. With values above 238dB/m, we selected a
conservative cut-off to deﬁne beginning signiﬁcant HS (S1).[24,25]
As a solid criteria for the prevalence of clinically apparent,
advanced steatosis, cut-off values of 260dB/m (S2) and 292dB/m
(S3) were applied.
2.4. Statistical analysis
Demographic, clinical, and laboratory characteristics stratiﬁed by
severity ofHSwere compared.Differences in continuous variables,
expressedasmedians, and1st and3rdquartileswereassessedusing
either nonparametric Mann–Whitney test or Kruskal–Wallis test.
Categorical variables, expressed as absolute frequencies and
percentages, were compared using Pearson chi squared test or
Fisher exact tests.A correlation analysis estimatedpossible impacts
on HS. Uni- and multivariable analyses were performed using
logistic and Cox-regression models. SPSS version 22 (IBM
Corporation, Armonk, NY) was used for statistical analysis.
3. Results
3.1. General characteristics of the cohort
In total, 364 patients were included in the study. The majority
wasmale (78%), Caucasian (76%), with amean age of 46 (range,
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20–75) years. The baseline characteristics of the study subjects
are shown in Table 1.
Two hundred and eighty seven patients (79%) were HIV
monoinfected, 20 (6%) patients were hepatitis B surface antigen-
positive, 57 (16%)wereanti-HCV-positive, ofwhich31 (54%)had
achieved sustained virologic response, 17 (31%) were HCV
therapynaïve, and9 (15%)either relapsedorwerenonresponder to
previously administered HCV treatments. Most of the patients
(95%) were treated with cART and showed undetectable plasma
HIV ribonucleic acid (83%). Ninety six (26%) patients were
classiﬁedasCenters forDiseaseControl andPrevention categoryC.
The mean CD4+ T cell count was 546 (range, 6–1478) cells/mm3.
Overweight, deﬁned by a BMI of at least 25 and less than 30kg/
m2, was observed in 93 (32%) and obesity, deﬁned by a BMI of at
least 30kg/m2, in 16 (6%) HIV monoinfected individuals
(Supplemental Table 2, http://links.lww.com/MD/C220). Twelve
(4%)HIVmonoinfected patients had the diagnosis of DM,with 9
(75%) receiving antidiabetic treatment and 10 (4%) presenting
HbA1c levels greater than 6.5%. Blood triglycerides of at least
150mg/dL were detected in 125 (43%), and blood HDL
cholesterol levels less than 40mg/dL were observed in 63
(22%) HIV monoinfected patients.
3.2. Prevalence of hepatic steatosis
Median CAP was 230 (range, 100–367) dB/m and 229dB/m
when including coinfected patients. Signiﬁcant HS, that is, CAP
≥238dB/m, was observed in 118 (41%) patients, of whom 34
(29%) had S1, 38 (32%) S2, and 46 (39%) S3. No signiﬁcant
difference in prevalence and distribution (41%, and 29%, 34%,
37%, respectively) of HS was observed in the coinfected patients
(Table 2, Supplementary Table 1, http://links.lww.com/MD/
C220).
Age, metabolic conditions (BMI, cholesterol, HDL, LDL, levels
of triglyceride, glucose, and HbA1c), and markers of liver injury
(alanine aminotransferase, gamma-glutamyltransferase) corre-
lated with altered CAP measurement, whereas HIV viral load
showed an inverse trend. Interestingly, the total duration of HIV
infection and the duration of cART showed positive correlations
with HS (Table 3). Similar ﬁndings were obtained when
considering the whole cohort (Supplemental Table 3, http://
links.lww.com/MD/C220).
As expected, patients with signiﬁcant steatosis showed higher
mean HbA1c levels (5.4 [3.6–11.4] vs5.2 [2.7–8.1] %; P= .007),
higher mean BMI (26 [19–36] vs 23 [16–41]kg/m2; P< .001),
higher triglyceride levels (183 [53–1193] vs 116 [28–753]mg/dL;
P< .001), and lowerHDL cholesterol (43 [18–100] vs 49 [8–127]
mg/dL; P= .004) compared to patients without steatosis. DM,
gender, and ethnicity revealed a signiﬁcant impact on HS
(Table 1). Interestingly, apart from gender, ethnicity also revealed
a signiﬁcant difference in median CAP values (Fig. 2A–D), with
higher levels in males and in Caucasians.
More severe steatosis was observed in patients with longer
duration of known HIV infection (9 [0–26] vs 7 [0–29] years;
Figure 1. Flow chart displaying selection of study participants (A). Prevalence and distribution of hepatic steatosis in all patients (B) and in HIV monoinfected
patients (C).
Mohr et al. Medicine (2018) 97:17 www.md-journal.com
3
P= .019], although uncontrolled HIV infection (viral load ≥40
copies/mL) did not have a statistically signiﬁcant inﬂuence on
CAP values (Table 2). However, patients in Centers for Disease
Control and Prevention class C had higher HS levels than patients
without acquired immune deﬁciency syndrome-deﬁning events
(P= .039) (Fig. 1E, F).
In contrast to liver ﬁbrosis development, no signiﬁcant
differences in HS were observed regarding anti-HCV positivity
(222dB/m), sustained virologic response (238dB/m), hepatitis B
surface antigen positivity (239dB/m), and HIV monoinfected
patients (229dB/m).
3.3. Factors associated with hepatic steatosis
Logistic regression analysis revealed that many demographic
(age, gender, and ethnicity), metabolic (BMI, triglyceride, DM
Table 2
HIV monoinfected population.
Variables All patients (n=289) S0 (n=171) S1 (n=34) S2 (n=38) S3 (n=46) P
Age (range), y 45 (20–75) 43 (20–75) 47 (30–73) 47 (25–74) 53 (33–74) .000
Male gender (no, %) 225 (78) 126 (74) 27 (79) 28 (74) 44 (96) .009
Caucasian (no, %) 215 (74) 115 (67) 28 (82) 31 (82) 41 (89) .007
African (no, %) 49 (17) 37 (22) 3 (9) 4 (11) 5 (11) .086
BMI (range), kg/m2 24 (16–41) 23 (16–41) 25 (19–29) 26 (20–36) 28 (20–36) .000
Cholesterol (range), mg/dL 197 (72–342) 189 (72–342) 199 (115–304) 206 (132–284) 218 (121–290) .000
HDL (range), mg/dL 49 (8–127) 51 (8–127) 50 (25–94) 48 (27–100) 40 (18–74) .001
LDL (range), mg/dL 120 (42–210) 115 (42–210) 125 (69–185) 129 (81–199) 133 (57–203) .013
Triglycerides (range), mg/dL 184 (28–1193) 146 (28–753) 164 (53–508) 231 (55–1048) 293 (76–1193) .000
AST/GOT (range), U/L 24 (9–147) 22 (9–65) 28 (14–147) 23 (12–41) 26 (16–61) .045
ALT/GPT (range), U/L 35 (8–151) 33 (8–99) 34 (17–78) 34 (17–50) 45 (20–151) .003
GGT (range), U/L 56 (12–568) 48 (12–340) 61 (22–295) 61 (20–157) 79 (22–568) .000
HbA1c (range), % 5.4 (2.7–11.4) 5.2 (2.7–8.1) 5.2 (3.6–7.2) 5.5 (4.9–7.9) 6.0 (3.8–11.4) .014
DM 2 (no, %) 12 (4) 3 (2) 0 (0) 2 (5) 7 (15) .000
On antidiabetics (no, %) 9 (75) 3 (100) 0 (0) 1 (50) 5 (71) .010
LPVr history (no, %) 79 (28) 39 (23) 9 (29) 9 (24) 22 (49) .024
Time since HIV diagnosis (range), y 9 (0–29) 9 (0–29) 11 (0–26) 9 (0–23) 10 (0–26) .104
Time cART naive (range), y 2 (0–17) 2 (0–17) 3 (0–12) 1 (0–7) 1 (0–12) .107
Time under cART (range), y 8 (0–23) 7 (0–23) 9 (0–19) 8 (0–23) 9 (0–22) .227
Baseline subject characteristics. overall and by signiﬁcant hepatic steatosis as determined by CAP ≥238kPa. Data are shown as median (IQR) or n (%). ALT= alanine aminotransferase, AST=aspartate
aminotransferase, BMI=body mass index, CAP= controlled attenuation parameter, cART= combined antiretroviral therapy, DM=diabetes mellitus, GGT=gamma-glutamyltransferase, GOT=glutamate-
oxalacetate-transaminase, GPT=glutamate-pyruvate-transaminase, HbA1c=glycated hemoglobin, HDL=high-density lipoprotein, HIV=human immunodeﬁciency virus, IQR= interquartile range, LDL= low-
density lipoprotein, LPVr= ritonavir-boosted lopinavir.
Table 1
Baseline characteristics.
Total study population HIV monoinfected patients
Variables
All patients
(n=364)
CAP<238
(n=215)
CAP≥238
(n=149)
P All patients
(n=289)
CAP<238
(n=171)
CAP≥238
(n=118) P
Age (range), y 46 (20–75) 43 (20–75) 49 (25–74) .0001 45 (20–75) 42 (20–75) 49 (25–74) .0001
Male gender (no, %) 285 (78) 159 (74) 126 (85) .010 225 (78) 126 (74) 99 (84) .027
Caucasian/African/other (no) 278/55/31 150/41/24 128/14/7 .0001 215/49/25 115/37/19 100/12/6 .001
CDC-C (no, %) 96 (26) 48 (22) 48 (32) .024 76 (26) 39 (23) 37 (31) .069
CD4 cells (range), cells/mm3 518 (6–1478) 496 (6–1478) 561 (29–1268) .036 502 (29–1478) 493 (37–1478) 545 (29–1268) .097
HIV viremia >40c/mL (no, %) 61 (17) 45 (21) 16 (11) .012 50 (17) 35 (21) 15 (13) .062
Time since HIV diagnosis (range), y 9 (0–29) 7 (0–29) 10 (0–29) .004 8 (0–29) 7 (0–29) 9 (0–26) .019
Time under cART (range), y 7 (0–27) 6 (0–27) 8 (0–24) .009 6 (0–23) 6 (0–23) 8 (0–23) .045
BMI (range), kg/m2 24 (15–41) 23 (15–41) 26 (19–36) .0001 24 (16–41) 23 (16–41) 26 (19–36) .0001
Cholesterol (range), mg/dL 192 (72–342) 185 (72–342) 205 (88–304) .003 198 (72–342) 188 (72–342) 209 (115–304) .0001
HDL (range), mg/dL 45 (8–127) 48 (8–127) 43 (18–100) .005 46 (8–127) 49 (8–127) 43 (18–100) .004
LDL (range), mg/dL 116 (41–210) 113 (42–210) 119 (41–203) ns 119 (42–210) 113 (42–210) 127 (57–203) .002
Triglycerides (range), mg/dL 139 (28–1549) 120 (28–1549) 176 (43–1193) .0001 139 (28–1193) 116 (28–753) 183 (53–1193) .0001
HbA1c (range), % 5.3 (2.7–11.4) 5.3 (2.7–8.1) 5.4 (3.6–11.4) .013 5.3 (2.7–11.4) 5.2 (2.7–8.1) 5.4 (3.6–11.4) .007
AST/GOT (range), U/L 22 (9–183) 21 (9–183) 23 (12–147) .055 21 (9–147) 20 (9–65) 22 (12–147) .035
ALT/GPT (range), U/L 31 (8–161) 29 (8–161) 33 (151–16) .007 30 (8–151) 29 (8–99) 32 (17–151) .004
GGT (range), U/L 44 (12–568) 40 (12–340) 49 (20–568) .001 43 (12–568) 39 (12–340) 50 (20–568) .0001
Chronic HCV/HBsAg-positive/SVR (no) 57/20/31 34/11/17 23/9 n.s.
LPVr history (no, %) 111 (31) 56 (26) 55 (37) .013 79 (28) 39 (23) 40 (34) .017
Baseline subject characteristics. Data are shown as median (IQR) or n (%). ALT= alanine aminotransferase, AST= aspartate aminotransferase, BMI=body mass index, CDC=Centers for Disease Control and
Prevention, GOT=glutamate-oxalacetate-transaminase, GPT=glutamate-pyruvate-transaminase, HBsAg=hepatitis B surface antigen, IQR= interquartile range, LPVr=ritonavir-boosted lopinavir, ns=not
statistical signiﬁcant, SVR= sustained virologic response.
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type 2, HbA1c, cholesterol, HDL, and LDL), and hepatic
parameters (aminotransferase and gamma-glutamyltransferase
levels), but not time since HIV diagnosis, were signiﬁcantly
associated with signiﬁcant HS. More parameters were found
when considering the whole cohort, suggesting that coinfection
might bias the analysis of risk factors for the development of
signiﬁcant steatosis in HIV infection (Supplemental Table 4,
http://links.lww.com/MD/C220). Subsequent multivariable anal-
ysis identiﬁed only BMI, HbA1c, and triglyceride levels as
independently associated with signiﬁcant HS (Table 4).
Regarding antiretroviral therapy only ritonavir-boosted lopi-
navir (LPV/r) was associated with the development of liver
steatosis. In the current study, no other PIs nor other
antiretroviral drug classes could be identiﬁed to have an impact
on the severity of steatosis. The effect of the duration of HIV
infection and cART duration mainly seems to depend on
metabolic changes (BMI, HbA1c, and triglycerides), which in
HIV monoinfected patients, are strongly and independently
associatedwithHS, while in the whole population, age also seems
to play an important role (Supplemental Table 4, http://links.
lww.com/MD/C220).
4. Discussion
Our ﬁndings outline that signiﬁcant HS is highly prevalent in
HIV-infected patients. Using CAP-derived data from a large and
unselected real-life cohort, this cross-sectional study is likely to be
more accurate than previous estimations.
Most published data on the prevalence of HS in HIV-infected
patients were obtained from liver biopsy studies in HIV/HCV
coinfected patients.[11,13,14] Even recently published data from a
prospective cohort holds a bias by including HCV coinfected
patients, as depending on the genotype, HCV might or might not
predispose to HS.[29] Usually, these patients have severe ﬁbrosis,
which impairs the CAP measurement.[30] Our study clearly focused
on HIV monoinfected patients to make the cohort less heteroge-
neous than previous studies. Although this study is not primarily
designed to compare mono- and coinfected patients, we found
Figure 2. Association between hepatic steatosis and gender, ethnicity, and CDC-C in all patients (A, C, E, respectively) and in HIV-monoinfected patients (B, D, F,
respectively). Data are presented as box plots. CDC=centers for disease control and prevention.
Table 3
Associations of CAP with different variables in HIV monoinfected
patients.
CAP
R P N
Body weight 0.502 .0001 283
BMI 0.49 .0001 274
Triglycerides 0.307 .0001 274
Age 0.322 .0001 289
Cholesterol 0.251 .0001 275
LDL 0.263 .0001 216
HbA1c 0.252 .0001 216
Glucose 0.223 .0001 276
HDL 0.209 .002 217
GGT 0.166 .006 274
GPT 0.16 .007 279
FIB4 0.177 .009 220
Creatinine 0.152 .011 278
Transient elastography 0.114 .054 289
APRI 0.086 .203 220
Cumulative cART duration 0.102 .093 271
Duration of HIV 0.09 .014 289
Correlations of patient characteristics and clinical parameters with HS assessed by CAP measurement.
APRI= aspartate aminotransferase to platelet ratio index, BMI=body mass index, CAP= controlled
attenuation parameter, cART= combined antiretroviral therapy, GGT=gamma-glutamyltransferase,
GPT=glutamate-pyruvate-transaminase, HbA1c=glycated hemoglobin, HDL=high-density lipopro-
tein, HIV=human immunodeﬁciency virus, HS=hepatic steatosis, LDL= low-density lipoprotein.
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evidence that many HIV-speciﬁc factors, which signiﬁcantly
correlate with CAP, are found only in the coinfected patients, such
as transient elastography, aspartate aminotransferase to platelet
ratio index score, HIV viral load, and duration of cART. These
factors are strongly associated with liver ﬁbrosis and inﬂammation,
which is another bias present in our previous studies.[7,31]
Other studies using liver biopsy, which is an invasive diagnostic
tool and not applicable for screening purpose, hold a signiﬁcant
selection bias. Steatosis involving at least 10% of hepatocytes can
be accurately detected applying a CAP cut-off of 238dB/m.[24,25]
Signiﬁcant steatosis was found in 41% of our study population,
with an emphasis on S2 and S3 steatosis. This is in line with 2
previously published CAP-based studies rendering the prevalence
of signiﬁcant HS in HIV-infected patients to about 30% to
40%.[15,17,18] Nevertheless, these data were either derived from a
much smaller cohort or included 20% to 50% patients with
concomitant chronic HCV infection. The 60% prevalence rate of
HS determined in a liver biopsy study, including 14 HIV
monoinfected patients with persistent liver enzyme elevations,
seems overestimated. Nevertheless, it showed that 26% of HIV-
infected patients without viral hepatitis, DM, or alcohol use
fulﬁlled the histological criteria for NASH.[22]
In the general population, increased BMI, insulin resistance, and
dyslipidemia are the main risk factors for NAFLD and NASH.[32]
NAFLD is characterized by greater hepatic uptake rates of plasma
fatty acids as a consequence of an increased release from an
expanded mass of adipose tissue with diminished insulin
responsiveness. Furthermore, hyperinsulinemia promotes the
upregulation of de novo lipogenesis in the liver.[32] In our study,
metabolic factors were strongly related to steatosis development.
Nevertheless, we observed higher rates of signiﬁcantHS compared
to the general population, where prevalence amounts up to
25%.[32] HIV itself induces metabolic changes, while long-term
exposure to antiretroviral drugs may also exert toxicities, which
could further contribute to the development of clinically relevant
liver disease.[8–10] Nucleoside analogue reverse transcriptase
inhibitors were in particular associated with mitochondrial
toxicity.[34] Impaired beta-oxidation of fatty acids leads to
increased hepatic lipid accumulation. Existing studies have found
no relationship between HS and individual antiretroviral
drugs.[6,13–16]However, our data show that LPV/r has a signiﬁcant
impact on the severity of steatosis. Whether this is due to a direct
drug effect or a secondary effect by the metabolic changes induced
by PIs cannot be determined with certainty.
Importantly, HIV-infected patients show an increase in BMI
shortly after starting cART. Especially those with a lower nadir
CD4 T-cell count, gained more lean mass and fat during the ﬁrst
96 weeks of cART.[35] This is consistent with our ﬁndings,
namely that a longer time since HIV diagnosis and longer periods
of cART are associatedwith presence of HS.However, these were
not independent associations but could predispose the patients to
metabolic changes, which ﬁnally were independent and strongly
associated with presence of HS. Possibly, the return-to-health
effect of cART is one of the reasons for the presence of HS in HIV
monoinfected patients. This is also supported by our previous
data, showing that cART and control of HIV replication is
protective for liver ﬁbrosis and liver injury in HIV monoinfected
patients. However, in these patients, HS might be induced by
other mechanisms and not be the result of direct hepatic effects of
HIV or cART. This may be supported by the ﬁnding of a gender
and ethnicity inﬂuence on CAP-value, despite the fact that these
patient groups were randomly distributed among the population.
The main limitations of this study are its cross-sectional design,
which limits the ability to evaluate change in variables of interest
over time, and the presence of a nonrandomized study
population. Homeostasis model assessment index to quantify
insulin resistance and dual-energy X-ray absorptiometry or
magnetic resonance tomography imaging to quantify body
composition changes were not available. Alcohol consumption as
well as anabolic use was self-reported by the patients, for
example, binge drinking behavior may have been underesti-
mated. No drug and anabolic screening tests were performed.
Finally, while liver biopsy remains the gold standard for the
assessment of HS, the acceptability and potential risks of biopsy
make its application difﬁcult for a large study population.
5. Conclusions
In conclusion, we found that prevalence of HS in HIV-infected
patients is higher than in the general population. Overweight,
dyslipidemia, and poorly controlled diabetes were independent
factors for HS in HIVmonoinfected patients. Suppression of viral
replication might contribute to the development of steatosis.
Controlling HIV replication might not condition liver disease by
causing metabolic disorders, instead, this may be due to the
return-to-health effect.
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